Sinusoidal obstruction syndrome (SOS) is a fatal complication after hematopoietic SCT. Although the etiology of SOS remains to be fully elucidated, previous studies suggested that preparative regimens cause damage to the sinusoidal endothelial cells leading to a hypercoagulable state and exaggerated cytokine production.
Recombinant thrombomodulin (rTM), a natural anticoagulant including the active extracellular domain of thrombomodulin, inactivates coagulation by binding to thrombin. 1 The thrombin-rTM complex activates protein C, which inactivates factors VIIIa and Va in the presence of protein S.
2 rTM was approved in 2008 in Japan based on a phase III clinical trial involving 234 patients with disseminated intravascular coagulation (DIC) associated with solid, hematological malignancies and infections. 2 The researchers concluded that use of rTM alleviates bleeding symptoms and improves prognosis of DIC compared with heparin. 2 Although little information is available on the efficacy of rTM in patients with diseases other than DIC, several researchers published case reports, which suggest the usefulness of rTM after allo-SCT. 3, 4 We experienced a case of a patient with SOS who developed fatal intracranial hemorrhage (ICH) during treatment with rTM. Detailed description on the case provides useful information on the safety of rTM after allogeneic SCT.
A 54-year-old man with acute myeloblastic leukemia underwent reduced-intensity cord blood transplantation because of secondary engraftment failure after allogeneic BMT from a one-locus mismatched unrelated donor with a preparative regimen comprising BU (16 mg/kg) and CY (120 mg/kg). The preparative regimen of the second transplantation included fludarabine (200 mg/m 2 ), CY (50 mg/kg) and 2 Gy of TBI. The GVHD prophylaxis comprised short-term MTX and tacrolimus.
On day 31, the patient complained of tenderness in the right upper quadrant, and demonstrated a weight gain of 3 kg. Abdominal ultrasonography showed hepatomegaly and accumulation of ascite. Laboratory examinations were as follows: aspartate aminotransferase, 30 U/L; alanine aminotransferase, 26 U/L; total bilirubin, 2.7 mg per 100 mL; creatinine, 0.9 mg per 100 mL. Microbiological examination of the blood was negative. A diagnosis of SOS was made based on the Seattle Criteria. 5 The antithrombin III concentrate was given at a dose of 1500 U for 3 days from day 31 to day 33. Platelets were repeatedly transfused to maintain its level of 42.0 Â 10 4 /mL (Figure 1) . rTM was administered at a dose of 130 U/kg on day 32, followed by 260 U/kg on days 33 and 34. Although serum levels of total bilirubin continued to be elevated, the abdominal pain was relieved after initiation of rTM.
On day 35, the patient developed sudden alteration of consciousness. The computed tomography of the brain revealed subarachnoid hemorrhage. Operations could not be performed due to poor general condition. The patient died due to brain herniation on day 42. Autopsy was not performed.
This case showed a possible association between the use of rTM and fatal ICH. Several findings support it. First, there was a close chronological relationship between the development of ICH and the use of rTM. The patient developed ICH on the third day of a course of treatment with rTM.
Second, risk factors for ICH after allogeneic SCT were managed in this patient. The incidence of ICH within 100 days of SCT was 1.9%, and most patients display severe thrombocytopenia at the onset of ICH. 6 The platelet count was kept above 2.2 Â 10 4 /mL before and after the onset of ICH in this patient, and other risk factors of ICH including hypertension were not documented. Although a target of 5.0 Â 10 4 /mL is sometimes used with other types of anticoagulants, maintaining a higher platelet count might be warranted in this situation to minimize this fatal complication. Finally, the safety of rTM was not verified except for patients with DIC. rTM might not be as safe in patients with DIC as in those with SOS, as the pathogenesis is different between SOS and DIC. Although DIC is characterized by the widespread activation of coagulation, occlusion of the hepatic veins with endothelial damage predominantly contributes to the pathogenesis of SOS. 8 Considering that rTM inhibits thrombosis in the hepatic veins, rTM seems to be promising for the treatment of SOS. However, bleeding risk of rTM might be substantial in patients with SOS, as these patients are usually thrombocytopenic and their coagulation functions are impaired. Further studies are warranted for the safety of rTM in patients with SOS.
In conclusion, this case suggested that the use of rTM was associated with fatal ICH in a patient with SOS. Although little information is available on the safety of rTM in patients without DIC, clinicians should notice this possibility of fatal complication.
